Boston Scientific (NYSE:BSX) Stock Sale Revealed by Rep. Kevin Hern

Key Points

• Rep. Kevin Hern sold $50,001–$100,000 of Boston Scientific stock on September 4 from the HERN FAMILY REVOCABLE TRUST account, alongside multiple recent sales of other holdings.
• Boston Scientific shares opened at $44.10, while the company reported quarterly EPS of $0.86 and revenue of $5.44 billion, exceeding analyst expectations; revenue rose 7.5% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $70.19, and company insiders—including the CEO—have bought approximately $9.4 million of stock over the past three months.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation NYSE: BSX. In a filing disclosed on September 25th, the Representative disclosed that they had sold between $50,001 and $100,000 in Boston Scientific stock on September 4th. The trade occurred in the Representative's "HERN FAMILY REVOCABLE TRUST" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of CenterPoint Energy NYSE: CNP on 9/15/2026.
• Sold $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of STERIS NYSE: STE on 9/15/2026.
• Sold $1,001 - $15,000 in shares of Seagate Technology NASDAQ: STX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 9/14/2026.
• Sold $15,001 - $50,000 in shares of IQVIA NYSE: IQV on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Emerson Electric NYSE: EMR on 9/14/2026.

Boston Scientific Trading Up 0.4%

Shares of BSX stock opened at $44.10 on Tuesday. The firm has a market capitalization of $63.92 billion, a P/E ratio of 17.86, a P/E/G ratio of 1.05 and a beta of 0.57. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock's fifty day simple moving average is $46.97 and its 200 day simple moving average is $52.24.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business's quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.27 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of several recent research reports. Argus restated a "hold" rating on shares of Boston Scientific in a research report on Friday, July 31st. Jefferies Financial Group decreased their price objective on Boston Scientific from $100.00 to $67.00 and set a "buy" rating for the company in a report on Wednesday, June 24th. Zacks Research lowered Boston Scientific from a "hold" rating to a "strong sell" rating in a research report on Friday, June 5th. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Finally, Weiss Ratings lowered Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, July 7th. Twenty-three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and an average price target of $70.19.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds and other institutional investors have recently bought and sold shares of the company. South Plains Financial Inc. bought a new position in shares of Boston Scientific in the 4th quarter worth about $39,000. Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific during the first quarter worth approximately $28,000. Cassaday & Co Wealth Management LLC bought a new stake in Boston Scientific in the first quarter worth approximately $32,000. Measured Wealth Private Client Group LLC lifted its stake in Boston Scientific by 244.9% in the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider's stock valued at $34,000 after buying an additional 387 shares during the period. Finally, Murphy & Mullick Capital Management Corp lifted its stake in Boston Scientific by 121.6% in the fourth quarter. Murphy & Mullick Capital Management Corp now owns 565 shares of the medical equipment provider's stock valued at $54,000 after buying an additional 310 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Insiders Place Their Bets

In related news, Director David C. Habiger purchased 2,100 shares of the firm's stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney bought 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 194,522 shares of company stock worth $9,385,210. Corporate insiders own 0.34% of the company's stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.